Adlai Nortye (NASDAQ:ANL) Shares Climb 10.9% – What’s Next?

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL)’s stock price traded up 10.9% during mid-day trading on Thursday. The company traded as high as $12.46 and last traded at $12.0650. Approximately 182,348 shares traded hands during trading, a decline of 50% from the average daily volume of 366,404 shares. The stock had previously closed at $10.88.

Analysts Set New Price Targets

ANL has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a report on Monday. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Adlai Nortye currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Adlai Nortye Stock Up 9.7%

The stock has a 50 day simple moving average of $14.52 and a two-hundred day simple moving average of $12.68.

Insider Buying and Selling

In other news, CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the sale, the chief financial officer owned 147,757 shares in the company, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the completion of the sale, the director directly owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. This trade represents a 7.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 26,881 shares of company stock worth $411,060.

Hedge Funds Weigh In On Adlai Nortye

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP acquired a new position in shares of Adlai Nortye in the second quarter valued at approximately $1,302,000. Braidwell LP purchased a new stake in Adlai Nortye during the second quarter worth about $9,145,000. Boone Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 2nd quarter worth approximately $2,971,000. ADAR1 Capital Management LLC purchased a new stake in Adlai Nortye during the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Adlai Nortye in the 1st quarter valued at about $1,140,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.